| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
October 25, 2022 |
|
|
| |
|
|
| |
|
|
|
Xtalks, online
2022 -10-31
As acceptance of flexible trial designs continues to advance, many sponsors are increasingly exploring alternate methods of dose escalation to support identification of a maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in open-label early phase or First-in-Human studies. Bayesian dose escalation designs have also coincided with advances in oncology therapy development, such as immunotherapies and antibody drug conjugates. These flexible methods may be more appropriate than those initially designed for chemotherapy drug development.
In this webinar, the featured speaker will discuss and cover:
Common types of open-label adaptive dose escalation designs
Comparisons with rule-based designs
How to apply and use these designs in oncology therapy development
How to determine which design is best suited for a clinical trial
Register to learn the benefits of Bayesian dose escalation designs for oncology therapy development.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Vanessa Beddo, PhD, VP, Biostatistical Consulting, Allucent
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2022 -10-31
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|